iSOFT introduces digital pathology with i-Path partnership

Banbury – 3 August 2010 – iSOFT Group Limited (ASX: ISF) today announced that it is to partner with Belfast-based i-Path Diagnostics to significantly boost its ability to deliver modern, web-based digital pathology solutions to its 150 pathology customers in the UK and the wider market.

iSOFT is adding i-Path's pioneering web-based platform as a module to iSOFT existing laboratory product suite. The aim is to deliver the solution under a software-as-a-service model, giving customers the opportunity to access data when and where they need it and the option to scale the solution to meet the needs of their organisation. The benefits of integrating digital pathology services into existing laboratory information systems include instant access to whole slide images and associated clinical data, the ability to digitally archive slides and the promotion of the role of the pathologist in multi-disciplinary team meetings.

Adrian Stevens, Managing Director of iSOFT's UK and Ireland business, said: "With a dominant market share, there is a huge opportunity here for iSOFT. The i-Path application will save customers time and money by eliminating the need to post glass slides and risk them being lost or broken.

"This is a hugely exciting opportunity. Over 150 customers attended the recent Laboratory User Convention held in Birmingham and had the opportunity to see i-Path solutions during a presentation made by Professor Peter Hamilton from Queen's University Hospital, Belfast."

Stuart Harvey, i-Path's Chief Executive Officer, said: "i-Path is very enthusiastic about the opportunities the iSOFT relationship will bring to both companies, in terms of boosting both product development and market share. The collaborative relationship will see the development of a fully integrated lab software in which i-Path's digital slide viewing technology will bring pathology data to life for the clinician. In partnering with i-Path, iSOFT is demonstrating a commitment to its customers to offer cutting edge digital pathology technology. Choosing i-Path as its partner is an indication of our credibility in the market as innovators and experts in this field."

i-Path's core product PathXL, is an innovative web-based software platform that enables glass slides used by pathologists to be converted into digital files and then accessed and distributed via NHS N3 network or the internet. Applications of this technology, known as Virtual Microscopy, facilitate education, training and research in the medical, biological and pharmaceutical sectors and are also emerging as a secondary diagnostic reporting tool.

End of release
You are currently subscribed to iSOFT News. If you no longer wish to receive these alerts please reply to this email with 'unsubscribe' in the subject line.

For further information contact:

Gary Cohen
Chief Executive Officer
iSOFT Group Limited
t: +61 2 8251 6700
e: gary.cohen@isofthealth.com

Brian Hemming
Corporate PR Manager
iSOFT Group Limited
t: +44 1295 274240
m: +44 7748 920528
e: brian.hemming@isofthealth.com

About iSOFT Group

iSOFT Group Limited (ASX: ISF) is the largest health information technology company listed on the Australian Securities Exchange, and among the world's biggest providers of advanced application solutions in modern healthcare economies.

iSOFT works with healthcare professionals to design and build software applications that answer all of the difficult questions posed by today's healthcare delivery challenges. Our solutions act as a catalyst for change, supporting free exchange of critical information across diverse care settings and participating organisations.

Today, more than 13,000 provider organisations in over 40 countries use iSOFT's solutions to manage patient information and drive improvements in their core processes. The group's sustainable development is delivered through careful planning, in-depth analysis of the market, and anticipation of our clients' evolving requirements. Our business is driven by the collective talent, experience and commitment of more than 4,700 specialists in 19 countries worldwide, including more than 2,700 technology and development professionals.

A global network of iSOFT subsidiaries, supported by an extensive partner network, provides substantial experience of national healthcare markets. As a result, we offer our clients comprehensive knowledge of local market requirements in terms of culture, language, working practices, regulation and organizational structure.

www.isofthealth.com

About i-Path Diagnostics

i-Path is a company focused on delivering high quality software solutions for virtual microscopy in the health sciences, biomedical, veterinary and pharmaceutical sectors.

Following significant investment, i-Path has grown significantly over the last few years, recruiting a team of highly skilled software developers, sales and customer support staff allowing them to develop and support a rapidly growing market for virtual microscopy and digital pathology.

i-Path also has a senior team of specialists with many years experience in tissue-based research and practice. It is a mature spin-out from Queen's University of Belfast and is closely allied to researchers in the Centre for Cancer Research and also a team of experienced pathologists from the Belfast Hospitals Trust. This multidisciplinary team strongly positions i-Path as a company that can be relied on to deliver innovative, effective and reliable solutions for the pathology and tissue research community.

i-Path provides PathXL to 10 universities in the UK and Europe as a pathology education and training system. Other i-Path customers include the London Deanery, The Pathological Society and the European Association of Pathology Chairs and Residency Program Directors (EAPCP).

Breaking fresh ground in the Pathology Research Market, i-Path delivers the only software as a service Tissue Microarray solution, the TMA Toolbox as well as Image Analysis software.